In a report released today, Matthew Sykes from Goldman Sachs reiterated a Buy rating on Myriad Genetics (MYGN – Research Report). The company’s shares closed yesterday at $16.34.
Sykes covers the Healthcare sector, focusing on stocks such as Quanterix, Qiagen, and Danaher. According to TipRanks, Sykes has an average return of -15.1% and a 31.96% success rate on recommended stocks.
Myriad Genetics has an analyst consensus of Hold, with a price target consensus of $20.33.
See Insiders’ Hot Stocks on TipRanks >>
Based on Myriad Genetics’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $183.5 million and a GAAP net loss of $116.1 million. In comparison, last year the company earned a revenue of $179.3 million and had a GAAP net loss of $14.1 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Myriad Genetics (MYGN) Company Description:
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual’s risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Read More on MYGN:
- Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
- Myriad Genetics appoints Raha as Chief Operating Officer
- Myriad Genetics Appoints Sam Raha as Chief Operating Officer
- Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023
- Is MYGN a Buy, Before Earnings?
